Vontobel Holding Ltd. Purchases 17,334 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Vontobel Holding Ltd. increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 32.5% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 70,643 shares of the medical research company's stock after purchasing an additional 17,334 shares during the period. Vontobel Holding Ltd.'s holdings in IQVIA were worth $12,454,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in IQV. Sowell Financial Services LLC bought a new stake in shares of IQVIA in the first quarter valued at approximately $305,000. SBI Securities Co. Ltd. acquired a new position in shares of IQVIA in the fourth quarter valued at $60,000. Park Avenue Securities LLC lifted its position in IQVIA by 40.4% in the first quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock worth $956,000 after purchasing an additional 1,562 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in IQVIA by 34.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company's stock worth $2,338,000 after buying an additional 3,398 shares in the last quarter. Finally, Jones Financial Companies Lllp increased its holdings in IQVIA by 57.0% in the 4th quarter. Jones Financial Companies Lllp now owns 1,215 shares of the medical research company's stock valued at $239,000 after buying an additional 441 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analyst Weigh In

IQV has been the subject of a number of analyst reports. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Wall Street Zen cut shares of IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Truist Financial lowered their price objective on IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th. Barclays cut their target price on IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 7th. Finally, Hsbc Global Res cut IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Eight research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $226.32.

IQVIA Trading Down 0.2%

IQVIA stock traded down $0.41 during trading hours on Friday, reaching $164.24. 674,106 shares of the company's stock traded hands, compared to its average volume of 1,651,146. The firm has a market capitalization of $28.41 billion, a price-to-earnings ratio of 22.38, a PEG ratio of 1.82 and a beta of 1.30. The company has a debt-to-equity ratio of 2.19, a quick ratio of 0.82 and a current ratio of 0.82. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The firm's 50 day moving average is $150.86 and its 200-day moving average is $173.29.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The business had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. During the same period in the prior year, the business posted $2.54 earnings per share. IQVIA's revenue was up 2.5% compared to the same quarter last year. On average, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.